SKU(재고 관리 코드):PAD559Hu01
Polyclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1)
Polyclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1)
Western blotting: 0.5-2µg/mL
;Immunohistochemistry: 5-20µg/mL
;Immunocytochemistry: 5-20µg/mL
;Optimal working dilutions must be determined by end user.
Product No.
PAD559Hu01
Organism Species
Homo sapiens (Human).
Source
Polyclonal antibody preparation
Host
Rabbit
Potency
n/a
Ig Type
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
RPD559Hu01-Recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
500µg/mL
Organism Species More
Mus musculus (Mouse), Rattus norvegicus (Rat), Sus scrofa; Porcine (Pig)
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against MAP2K1. It has been selected for its ability to recognize MAP2K1 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.5-2µg/mL
Immunohistochemistry: 5-20µg/mL
Immunocytochemistry: 5-20µg/mL
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
Magazine |
Citations |
Graefe's Archive for Clinical and Experimental Ophthalmology |
Role of RhoA/MERK1/ERK1/2/iNOS signaling in ocular ischemic syndrome pubmed:27538909 |
PLOS ONE |
Identification of Biomarkers of Impaired Sensory Profiles among Autistic Patients. pubmed:27824861 |
Cancers |
Rationale for a Combination Therapy Consisting of MCL1-and MEK-Inhibitors in Acute Myeloid Leukemia Pubmed: 31718075 |
Cancers (Basel) |
BMI1-Inhibitor PTC596 in Combination with MCL1 Inhibitor S63845 or MEK Inhibitor Trametinib in the Treatment of Acute Leukemia. Cancers 2021, 13, 581 33540760 |
Catalog No. |
Related products for research use of Homo sapiens (Human) Organism species |
Applications (RESEARCH USE ONLY!) |
RPD559Hu01 |
Recombinant Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) |
Positive Control; Immunogen; SDS-PAGE; WB. |
PAD559Hu01 |
Polyclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) |
WB; IHC; ICC; IP. |
MAD559Hu21 |
Monoclonal Antibody to Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) |
WB; IHC; ICC; IP. |
SED559Hu |
ELISA Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) |
Enzyme-linked immunosorbent assay for Antigen Detection. |
LMD559Hu |
Magnetic Luminex Assay Kit for Mitogen Activated Protein Kinase Kinase 1 (MAP2K1) ,etc. |
Magnetic Luminex Assay for Antigen Detection. |